196 related articles for article (PubMed ID: 24119899)
1. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
Wang H; Satoh M; Abe H; Sunamura M; Moriya T; Ishidoya S; Saito S; Hamada H; Arai Y
Urology; 2006 Sep; 68(3):674-81. PubMed ID: 16979729
[TBL] [Abstract][Full Text] [Related]
3. E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma.
Wang H; Satoh M; Chen GP; Li DC; Hamada H; Arai Y
Chin Med J (Engl); 2011 Apr; 124(7):1082-7. PubMed ID: 21542972
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor efficacy of integrin-targeted oncolytic adenovirus AxdAdB3-F/RGD on bladder cancer.
Wang H; Cai Z; Yang F; Luo J; Satoh M; Arai Y; Li D
Urology; 2014 Feb; 83(2):508.e13-9. PubMed ID: 24315309
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Isono M; Okubo K; Asano T; Sato A
Sci Rep; 2021 May; 11(1):10181. PubMed ID: 33986399
[TBL] [Abstract][Full Text] [Related]
6. Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
Mao L; Yang C; Li L; Nai L; Fan L; Wang J; Li W; Wen R; Chen J; Zheng J
Tumour Biol; 2014 Jun; 35(6):5937-44. PubMed ID: 24604329
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Zhang X; Taoka R; Liu D; Matsuoka Y; Tohi Y; Kakehi Y; Sugimoto M
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921102
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.
Seo HK; Ahn KO; Jung NR; Shin JS; Park WS; Lee KH; Lee SJ; Jeong KC
Oncotarget; 2014 Jan; 5(2):326-37. PubMed ID: 24504118
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine in bladder cancer.
El Karak F; Flechon A
Expert Opin Pharmacother; 2007 Dec; 8(18):3251-6. PubMed ID: 18035967
[TBL] [Abstract][Full Text] [Related]
10. A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
Weber HL; Gidekel M; Werbajh S; Salvatierra E; Rotondaro C; Sganga L; Haab GA; Curiel DT; Cafferata EG; Podhajcer OL
Clin Cancer Res; 2015 Apr; 21(7):1665-74. PubMed ID: 25573380
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
[TBL] [Abstract][Full Text] [Related]
13. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer.
Brocks CP; Büttner H; Böhle A
J Urol; 2005 Sep; 174(3):1115-8. PubMed ID: 16094076
[TBL] [Abstract][Full Text] [Related]
15. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Kerr M; Scott HE; Groselj B; Stratford MR; Karaszi K; Sharma NL; Kiltie AE
Clin Cancer Res; 2014 Nov; 20(21):5435-45. PubMed ID: 25224279
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
[TBL] [Abstract][Full Text] [Related]
17. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
Fukuda K; Abei M; Ugai H; Seo E; Wakayama M; Murata T; Todoroki T; Tanaka N; Hamada H; Yokoyama KK
Cancer Res; 2003 Aug; 63(15):4434-40. PubMed ID: 12907616
[TBL] [Abstract][Full Text] [Related]
18. β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.
Kallifatidis G; Smith DK; Morera DS; Gao J; Hennig MJ; Hoy JJ; Pearce RF; Dabke IR; Li J; Merseburger AS; Kuczyk MA; Lokeshwar VB; Lokeshwar BL
Mol Cancer Ther; 2019 Apr; 18(4):801-811. PubMed ID: 30787175
[TBL] [Abstract][Full Text] [Related]
19. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
20. E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer.
Fukuda K; Abei M; Ugai H; Kawashima R; Seo E; Wakayama M; Murata T; Endo S; Hamada H; Hyodo I; Yokoyama KK
Cancer Gene Ther; 2009 Feb; 16(2):126-36. PubMed ID: 18818710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
